USA flag logo/image

An Official Website of the United States Government

Human/Pig Model of Hepatitis C Virus for New Vaccines

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71146
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI058332
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
XIMEREX, INC.
2614 N. 161 AVE. OMAHA, NE -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Human/Pig Model of Hepatitis C Virus for New Vaccines
Agency: HHS
Contract: 1R43AI058332-01
Award Amount: $640,964.00
 

Abstract:

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) has emerged as a major public health problem. World wide, as many as 200 million people are infected. In the United States, an estimated 3.9 million are infected, with 2.7 million Americans chronically infected. The immune response of the patient determines if the patient is cured of the virus, develops a lifelong infection, or develops severe liver disease. Progress in the treatment and prevention of HCV is severely hampered by the lack of a suitable animal model. Chimpanzees are the only animals other than humans that are infected with HCV. The pathogenesis differs from human hepatitis, however. Furthermore, the ethics and availability of chimpanzees limits the studies that can be done. A promising model was recently developed by engrafting human hepatocytes in immune deficient mice. This model, however, cannot assess the immune response to the virus or vaccines. We have developed technology for engrafting human liver cells in immune competent pigs. The innovations include transplanting cells into fetal pigs in utero and the development of unique transgenic pigs that enhance the growth of human liver cells. This study will inoculate HCV into hybrid swine with human liver cells and evaluate the virus proliferation, monitor the persistence of the virus and liver disease, and characterize the immune response. A large animal immune compentent model of HCV will lead to a better understanding of the pathogenesis of hepatitis C virus and to more effective vaccines and immune therapy.

Principal Investigator:

William E. Beschorner
4025592235
BESCHORNER@XIMEREX.COM

Business Contact:


4025592235
Small Business Information at Submission:

XIMEREX, INC.
2614 N. 161 AVE. OMAHA, NE 68116

EIN/Tax ID: 521839842
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No